8. Edwards Lifesciences
R&D spending: $622,200,000
Percentage of revenues: 16.7%
2019 overall revenue ranking: 26
A considerable amount of Edwards Lifesciences’s research and development investments went toward clinical trials, according to the company’s annual report.
The company said it is developing new products in transcatheter aortic valve replacement to streamline transcatheter aortic heart valve replacement procedures while developing pulmonic platforms to expand therapies for congenital heart disease patients.
Edwards Lifesciences said it is making significant investments in developing technologies to treat mitral and tricuspid valve diseases and other structural heart conditions.